Sangeetha Satyan, MD
Nephrology · Dover, DENPI 1447453915
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 239 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations.
Across 239 payments — averaging $25.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$745
- Amgen$676
- Vifor Pharma, Inc.$503
- Fresenius USA Marketing, Inc.$493
- Ardelyx, Inc.$366
- Akebia Therapeutics Inc$363
- plus $3K from 30 others
What the payments were for
- Food & beverage$5,78296%
- Education$2364%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 19 | $745 |
| Amgen(2 entities) | 26 | $676 |
| Vifor Pharma, Inc. | 16 | $503 |
| Fresenius USA Marketing, Inc. | 23 | $493 |
| Ardelyx, Inc. | 9 | $366 |
| Akebia Therapeutics Inc | 19 | $363 |
| Bayer | 15 | $311 |
| Aurinia Pharma U.S., Inc. | 11 | $274 |
| Mallinckrodt Hospital Products Inc. | 7 | $233 |
| Sanofi | 9 | $225 |
| Calliditas Therapeutics US Inc. | 6 | $225 |
| Otsuka America Pharmaceutical, Inc. | 9 | $214 |
| GSK | 9 | $184 |
| Travere Therapeutics, Inc. | 12 | $164 |
| ANI Pharmaceuticals, Inc. | 6 | $137 |
| Novartis | 4 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $98 |
| Boehringer Ingelheim | 6 | $93 |
| Amicus Therapeutics, Inc. | 3 | $70 |
| Mozarc Medical US LLC | 2 | $60 |
| Novo Nordisk | 3 | $55 |
| Mallinckrodt Enterprises LLC | 2 | $48 |
| Lilly USA, LLC | 2 | $44 |
| Kyowa Kirin, Inc. | 2 | $44 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $42 |
| OPKO Pharmaceuticals, LLC | 2 | $41 |
| Scpharmaceuticals Inc. | 2 | $34 |
| Shield Therapeutics Inc | 1 | $32 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Angiodynamics, Inc. | 1 | $23 |
| Nxstage Medical, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Shire North American Group Inc | 1 | $16 |
| Biomerieux Inc | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XPHOZAH 30 MG$230
- Veltassa$227
- ULTOMIRIS$125
- TARPEYO$110
How this compares
$6,019 in reported general payments places this provider in the 80th percentile of 49 nephrology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 154 | $178,996 |
| JardianceEmpagliflozin | 108 | $143,672 |
| KerendiaFinerenone | 21 | $34,984 |
| AuryxiaFerric Citrate | 14 | $30,235 |
| VelphoroSucroferric Oxyhydroxide | 14 | $30,187 |
| DapagliflozinDapagliflozin Propanediol | 11 | $11,082 |
| Cinacalcet Hcl | 38 | $9,205 |
| Calcitriol | 88 | $2,509 |
| Sevelamer Carbonate | 12 | $1,682 |
| Potassium Chloride | 55 | $1,537 |
| Losartan Potassium | 129 | $1,306 |
| Lisinopril | 81 | $676 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 48 | $481 |
| Hydralazine Hcl | 23 | $470 |
| Valsartan | 15 | $413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $745 | $178,996154 claims |
| Boehringer IngelheimJardiance | $93 | $143,672108 claims |
| BayerKerendia | $311 | $34,98421 claims |
| Akebia Therapeutics IncAuryxia | $363 | $30,23514 claims |
| Fresenius USA Marketing, Inc.Velphoro | $493 | $30,18714 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $137 | $41315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 49 nephrology providers in Delaware.
Other nephrology in Dover
- Gerald MilanDover$16K
- Gertrude Findley-ChristianDover$8K
- Sumanth KacharamDover$7K
- Svastijaya DaviratanasilpaDover$5K
- Manmeet BrarDover$2K
- Daniel CoarDover$721
- Lakshmi MenonDover$141
- Prayus TailorNewark$127K
- William DahmsNewark$94K
- Theodore SaadNewark$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.